stockrow
Friday 6 November 2026
Export TMDX’s income statement to Excel — free account
TransMedics Group, Inc.
TMDX Healthcare Medical Devices
TransMedics Group, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $605.5 million, up 37.1% from fiscal 2024.
- Revenue
- +41.2%
- EPS
- −31.0%
- Free cash flow
- −55.4%
- Total debt
- −89.3%
Quarter to September 2026, against a year earlier
87.65
18.67
+27.07%
Follow TMDX
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 From the 10-Q filed 5 Nov | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
21.80 | 19.76 | 15.03 | 19.87 |
P/S ratio |
6.83 | 5.38 | 3.44 | 3.98 | |
P/FCF ratio |
30.96 | 22.58 | 29.06 | 64.77 | |
P/Operating CF |
119.82 | 139.33 | 132.69 | 80.41 | |
P/B ratio |
8.74 | 6.92 | 4.43 | 5.26 | |
Price to Tangible BV |
9.00 | 7.08 | 4.53 | 5.37 | |
EV/Sales |
6.87 | 6.00 | 4.02 | 4.53 | |
EV/EBITDA |
30.64 | 29.94 | 22.76 | 26.00 | |
EV/Operating CF |
21.57 | 17.32 | 18.40 | 29.36 | |
EV/FCF |
31.14 | 25.19 | 33.98 | 73.80 | |
Quick Ratio |
6.41 | 6.01 | 5.87 | 3.98 | |
Current Ratio |
7.14 | 6.74 | 6.63 | 4.53 | |
Net Debt/EBITDA |
0.84 | 15.71 | 11.45 | (11.24) | |
Debt/Assets |
47.96% | 59.73% | 58.84% | 3.61% | |
Debt/Equity |
1.08 | 1.73 | 1.66 | 0.10 | |
Asset Turnover |
0.65 | 0.56 | 0.57 | 0.59 | |
Operating CF/Net income |
0.33 | 3.35 | 1.18 | 2.11 | |
Capex/Depreciation |
(2.08) | (3.09) | (0.69) | (0.77) | |
Interest Coverage |
6.34 | 1.85 | 3.29 | 3.87 | |
Research and Development Expense of Revenue |
12.88% | 14.30% | 16.65% | 14.38% | |
Selling, General and Administrative Expense of Revenue |
32.00% | 36.21% | 30.45% | 30.21% | |
Intangible Assets out of Total Assets |
0.01 | 0.01 | 0.01 | 0.00 | |
Share Based Compensation of Revenue |
5.84% | 5.72% | 4.53% | 6.21% | |
Graham Net Nets |
0.01 | (0.09) | (0.13) | (0.09) | |
Graham Number |
41.80 | 40.32 | 38.60 | 38.73 | |
Earnings Yield |
4.59% | 5.06% | 6.65% | 5.03% | |
Free Cash Flow Yield |
3.23% | 4.43% | 3.44% | 1.54% | |
Revenue per Share |
4.73 | 5.06 | 5.49 | 5.85 | |
Operating CF per Share |
1.02 | 0.71 | 0.50 | 1.04 | |
Capex per Share |
(0.46) | (1.07) | (0.21) | (0.24) | |
Free Cash Flow per Share |
0.56 | (0.35) | 0.30 | 0.80 | |
Cash per Share |
14.37 | 13.43 | 13.67 | 14.21 | |
Shareholders Equity per Share |
13.92 | 14.37 | 14.98 | 15.87 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
13.92 | 14.37 | 14.98 | 15.87 | |
Free Cash Flow |
19.00 | (12.12) | 10.22 | 27.60 | |
Working Capital |
548.48 | 527.36 | 552.84 | 539.60 | |
Capital Expenditures |
(15.51) | (36.66) | (7.09) | (8.40) | |
Net Current Asset Value |
42.51 | (321.53) | (295.22) | (274.77) | |
EV/EBIT |
38.31 | 40.38 | 32.91 | 38.16 | |
Capex to Sales |
0.10 | 0.21 | 0.04 | 0.04 | |
Price to Operating Income |
38.08 | 36.19 | 28.15 | 33.49 | |
| Other line items | |||||
Average Receivables |
91.00 | 116.38 | 104.49 | 97.82 | |
Average Payables |
10.32 | 10.87 | 11.22 | 11.15 | |
Average Inventory |
47.72 | 46.64 | 46.50 | 51.44 | |
Average Assets |
936.22 | 1,136.18 | 1,177.46 | 1,231.98 | |
Average Common Equity |
350.85 | 380.16 | 418.08 | 452.96 |
Columns are period end dates · fundamentals updated 5 Nov 2026